Abstract
SARS-CoV-2 pandemic has had a significant impact on the entire society and especially on its vulnerable group, such as drug users. The aim of the study was to determine the behavioral patterns of users of state methadone replacement therapy (MRT) programs during the pandemic. The study was conducted in four focus groups. As a result of the research, it was determined: SARS-CoV-2 the pandemic had a significant impact on the patients. As a positive factor, the fact that the relationship with medical institutions and the information received from them significantly increased the awareness of patients in terms of the prevention of Covid-19. At the same time, patients noted an increase in anxiety related to their and their loved ones being infected with Covid-19. The measures implemented by the state to prevent the spread of Covid-19 in the programs of MRT (taking home a 5-day dose of replacement medicine) caused a double result: Most patients find that it improves their mood and sense of comfort. At the same time, there was an increase in the misuse of drugs taken at home (injection use, taking a 5-day dose in 3-4 days and then using other drugs/psychotropic substances), and in rare cases, there was an alienation/exchange of belonging methadone for street drugs. These findings are important for the future planning and implementation of opioid substitution therapy (OST) programs.
References
Cai A, Calhoun DA. Resistant Hypertension: An Update of Experimental and Clinical Findings. Hypertension. 2017 Jul;70(1):5-9. doi: 10.1161/HYPERTENSIONAHA.117.08929. Epub 2017 May 15. PMID: 28507173; PMCID: PMC5515281.
Barrios V, Escobar C. Resistant hypertension. What is the best approach? Rev Esp Cardiol. 2009 Jun;62(6):711-2; author reply 712. English, Spanish. doi: 10.1016/s1885-5857(09)72244-3. PMID: 19480775.
Basting T, Lazartigues E. DOCA-Salt Hypertension: an Update. Curr Hypertens Rep. 2017 Apr;19(4):32. doi: 10.1007/s11906-017-0731-4. PMID: 28353076; PMCID: PMC6402842.
Lerman LO, Kurtz TW, Touyz RM, Ellison DH, Chade AR, Crowley SD, Mattson DL, Mullins JJ, Osborn J, Eirin A, Reckelhoff JF, Iadecola C, Coffman TM. Animal Models of Hypertension: A Scientific Statement From the American Heart Association. Hypertension. 2019 Jun;73(6):e87-e120. doi: 10.1161/HYP.0000000000000090. PMID: 30866654; PMCID: PMC6740245.
Rodriguez-Iturbe B, Pons H, Johnson RJ. Role of the Immune System in Hypertension. Physiol Rev. 2017 Jul 1;97(3):1127-1164. doi: 10.1152/physrev.00031.2016. PMID: 28566539; PMCID: PMC6151499.
Lee WK, Padmanabhan S, Dominiczak AF. Genetics of hypertension: from experimental models to clinical applications. J Hum Hypertens. 2000 Oct-Nov;14(10-11):631-47. doi:10.1038/sj.jhh.1001043. PMID: 11095156.
Graham D, McBride MW, Brain NJ, Dominiczak AF. Congenic/consomic models of hypertension. Methods Mol Med. 2005;108:3-15. doi: 10.1385/1-59259-850-1:003. PMID: 16028672.
Pestana-Oliveira N, Nahey DB, Johnson T, Collister JP. Development of the Deoxycorticosterone Acetate (DOCA)salt Hypertensive Rat Model. Bio Protoc. 2020 Aug 5;10(15):e3708. doi: 10.21769/BioProtoc.3708. PMID: 33659372; PMCID: PMC7842531.
Pinto YM, Paul M, Ganten D. Lessons from rat models of hypertension: from Goldblatt to genetic engineering. Cardiovasc Res. 1998 Jul;39(1):77-88. doi: 10.1016/s0008-6363(98)00077-7. PMID: 9764191.
Bigiarelli KJ. Rodent Thermoregulation: Considerations for Tail-Cuff Blood Pressure Measurements. J Am Assoc Lab Anim Sci. 2022 Sep 1;61(5):406-411. doi: 10.30802/AALAS-JAALAS-22-000006. Epub 2022 Aug 10. PMID: 35948400; PMCID: PMC9536829.
Shreenivas S, Oparil S. The role of endothelin-1 in human hypertension. Clin Hemorheol Microcirc. 2007;37(1-2):157-78. PMID: 17641406.
Gomez-Sanchez EP. DOCA/Salt: Much More Than a Model of Hypertension. J Cardiovasc Pharmacol. 2019 Nov;74(5):369-371. doi: 10.1097/FJC.0000000000000753. PMID: 31599781.
Yemane H, Busauskas M, Burris SK, Knuepfer MM. Neurohumoral mechanisms in deoxycorticosterone acetate (DOCA)-salt hypertension in rats. Exp Physiol. 2010 Jan;95(1):51-5. doi: 10.1113/expphysiol.2008.046334. Epub 2009 Aug 21. PMID: 19700514.
Kandlikar SS, Fink GD. Mild DOCA-salt hypertension: sympathetic system and role of renal nerves. Am J Physiol Heart Circ Physiol. 2011 May;300(5):H1781-7. doi: 10.1152/ajpheart.00972.2010. Epub 2011 Feb 25. PMID: 21357502; PMCID: PMC3094082.
Lilach O. Lerman, Theodore W. Kurtz, Rhian M. Touyz, Animal Models of Hypertension: A Scientific Statement from the American Heart Association, Hypertension. 2019; 73:e87–e120, doi.org/10.1161/HYP.0000000000000090
Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction.J Exp Med. 2007; 204:2449–2460. doi: 10.1084/jem.20070657
Pestana-Oliveira N, Nahey DB, Johnson T, Collister JP. Development of the Deoxycorticosterone Acetate (DOCA)-salt Hypertensive Rat Model. Bio Protoc. 2020 Aug 5;10(15):e3708. doi: 10.21769/BioProtoc.3708. PMID: 33659372; PMCID: PMC7842531.